What smart money is saying about Linc
1 fund in our archive has pitched Linc — most recently Kavaljer Investmentbolagsfond in September 2026.
Linc AB is a private equity and venture capital firm, specializing in early and mature stage investments in pharmaceutical, life-science and med-tech companies. It prefers to invest in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses. The investments are made in both private and public companies and in research and operational companies. The firm prefers to invest in Nordic companies. It usually invests from SEK 25 million ($2.99 million) and SEK 250 million ($29.99 million), the first investment often being a relatively small one and the follow-up investments comprising the larger part of the investment. Linc AB was founded in 1991 and based in Stockholm, Sweden.
Get an email when a fund writes about it
Position history
Every position in Linc on record in the archive was reported in Q3 2026, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 1 |
Fund activity · 1 position
- September 2026
“Linc Buybacks, NAV discount and a strong balance sheet Linc gives the fund similar exposure to healthcare as HBM Healthcare and BB Biotech, but with a focus on Nordic companies. The company invests in both listed and unlisted life science companies, with an emphasis on pharmaceuticals and medical technology. Since the sale of Calliditas, Linc has been overcapitalized, with liquid assets equal to just over 27% of net asset value. At the same time, the share trades at about a 13% discount to net asset value, which makes the buyback program a value-creating way to use the capital. The fund has a positive view of Linc's core holdings MedCap and Stille, which continue to develop well. The unlisted portfolio has performed more weakly, but conditions are judged to improve as the market climate for the sector recovers. With a strong balance sheet, Linc is also well positioned to take advantage of investment opportunities that may arise in the market. Linc constitutes 4.0% of Kavaljer Investmentbolagsfond.”
Linc
Fund coverage · 1 thesis
- Kavaljer InvestmentbolagsfondSeptember 2026
Linc invests in Nordic life science companies and is seen as attractive due to its NAV discount, buybacks, and strong balance sheet.
Read the full thesis
Read every full thesis on Linc
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→